Alteration of vitamin D metabolic enzyme expression and calcium transporter abundance in kidney involved in type 1 diabetes-induced bone loss

Osteoporosis International

Volumn 22, Issue 6, 2011, Pages 1781-1788

  Zhang, Y ^a   Papasian, C J ^b   Deng, H W ^a,b  

^a UNIVERSITY OF SHANGHAI FOR SCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone; Calcium; Kidney; Type 1 diabetes; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D 1ALPHA HYDROXYLASE; 25 HYDROXYVITAMIN D 24 HYDROXYLASE; CALCIUM BINDING PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; OXYGENASE; PLASMA MEMBRANE CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; STREPTOZOCIN; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 6; VITAMIN D; VITAMIN D RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; BONE DENSITY; BONE STRUCTURE; CALCIUM EXCRETION; CALCIUM URINE LEVEL; CELL MEMBRANE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE TARGETING; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METAPHYSIS; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; TRABECULAR BONE; UPREGULATION; WESTERN BLOTTING;

EID: 85027941169     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1404-1     Document Type: Conference Paper

References (44)

1. Tao B, Liu JM, Zhao HY, Sun LH, Wang WQ, Li XY, Ning G (2008) Differences between measurements of bone mineral densities by quantitative ultrasound and dual-energy X-ray absorptiometry in type 2 diabetic postmenopausal women. J Clin Endocrinol Metab 93:1670-1675 (Pubitemid 351656503)
2. Schwartz AV, Sellmeyer DE (2007) Diabetes, fracture, and bone fragility. Curr Osteoporos Rep 5:105-111 (Pubitemid 47571960)
3. Räkel A, Sheehy O, Rahme E, LeLorier J (2008) Osteoporosis among patients with type 1 and type 2 diabetes. Diab Metab 34:193-205
4. McCabe LR (2007) Understanding the pathology and mechanisms of type I diabetic bone loss. J Cell Biochem 102:1343-1357 (Pubitemid 350223938)
5. Martin LM, McCabe LR (2007) Type I diabetic bone phenotype is location but not gender dependent. Histochem Cell Biol 128:125-133 (Pubitemid 47197932)
6. Hofbauer LC, Brueck CC, Singh SK, Dobnig H (2007) Osteoporosis in patients with diabetes mellitus. J Bone Miner Res 22:1317-1328 (Pubitemid 351339677)
7. Saller A, Maggi S, Romanato G, Tonin P, Crepaldi G (2008) Diabetes and osteoporosis. Aging Clin Exp Res 20:280-289
8. Nickolas TL, Leonard MB, Shane E (2008) Chronic kidney disease and bone fracture: a growing concern. Kidney Int 74:721-731
9. Szkudelski T (2001) The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 50:536-546
10. Altan MF, Kanter M, Donmez S, Kartal ME, Buyukbas S (2007) Combination therapy of Nigella sativa and human parathyroid hormone on bone mass, biomechanical behavior and structure in streptozotocin-induced diabetic rats. Acta Histochem 109:304-314 (Pubitemid 46962080)
11. Ogasawara A, Nakajima A, Nakajima F, Goto K, Yamazaki M (2008) Molecular basis for affected cartilage formation and bone union in fracture healing of the streptozotocin-induced diabetic rat. Bone 43:832-839
12. Yamaguchi M, Uchiyama S, Lai YL (2007) Oral administration of phytocomponent p-hydroxycinnamic acid has a preventive effect on bone loss in streptozotocin-induced diabetic rats. Int J Mol Med 19:803-807
13. Kanter M, Altan MF, Donmez S, Ocakci A, Kartal ME (2007) The effects of quercetin on bone minerals, biomechanical behavior, and structure in streptozotocin-induced diabetic rats. Cell Biochem Funct 25:747-752 (Pubitemid 351202365)
14. Uchiyama S, Yamaguchi M (2005) Oral administration of betacryptoxanthin prevents bone loss in streptozotocin-diabetic rats in vivo. Biol Pharm Bull 28:1766-1769 (Pubitemid 41324149)
15. Suzuki K, Miyakoshi N, Tsuchida T, Kasukawa Y, Sato K, Itoi E (2003) Effects of combined treatment of insulin and human parathyroid hormone (1-34) on cancellous bone mass and structure in streptozotocin-induced diabetic rats. Bone 33:108-114 (Pubitemid 36952692)
16. Yamaguchi M, Uchiyama S (2003) Preventive effect of zinc acexamate administration in streptozotocin-diabetic rats: restoration of bone loss. Int J Mol Med 12:755-761
17. Motyl KJ, McCabe LR (2009) Leptin treatment prevents type I diabetic marrow adiposity but not bone loss in mice. J Cell Physiol 218:376-384
18. Hie M, Shimono M, Fujii K, Tsukamoto I (2007) Increased cathepsin K and tartrate-resistant acid phosphatase expression in bone of streptozotocin-induced diabetic rats. Bone 41:1045-1050 (Pubitemid 350116747)
19. Quarles LD (2008) Endocrine functions of bone in mineral metabolism regulation. J Clin Investig 118:3820-3828
20. Zhang Y, Leung PC, Che CT, Chow HK, Wu CF, Wong MS (2008) Improvement of bone properties and enhancement of mineralization by ethanol extract of Fructus Ligustri Lucidi. Br J Nutr 99:494-502 (Pubitemid 351223417)
21. Zhang Y, Dong XL, Leung PC, Che CT, Wong MS (2008) Fructus ligustri lucidi extract improves calcium balance and modulates the calciotropic hormone level and vitamin D-dependent gene expression in aged ovariectomized rats. Menopause 15:558-565 (Pubitemid 351681639)
22. Zhang Y, Lai WP, Leung PC, Che CT, Wong MS (2008) Improvement of Ca balance by Fructus Ligustri Lucidi extract in aged female rats. Osteoporos Int 19:235-242
23. Strehler EE, Caride AJ, Filoteo AG, Xiong Y, Penniston JT, Enyedi A (2007) Plasma membrane Ca2+ ATPases as dynamic regulators of cellular calcium handling. Ann NY Acad Sci 1099:226-236 (Pubitemid 47092589)
24. Zhang Y, Lai WP, Wu CF, Favus MJ, Leung PC, Wong MS (2007) Ovariectomy worsens secondary hyperparathyroidism in mature rats during low Ca diet. Am J Physiol Endocrinol Metab 292:E723-E731 (Pubitemid 46411049)
25. Hendrix I, Anderson P, May B, Morris H (2004) Regulation of gene expression by the CYP27B1 promoter-study of a transgenic mouse model. J Steroid Biochem Mol Biol 89-90:139-142 (Pubitemid 38844274)
26. Qi Z, Fujita H, Jin J, Davis LS, Wang Y, Fogo AB, Breyer MD (2005) Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 54:2628-2637 (Pubitemid 41233584)
27. Silva MJ, Brodt MD, Lynch MA, McKenzie JA, Tanouye KM, Nyman JS, Wang X (2009) Type 1 diabetes in young rats leads to progressive trabecular bone loss, cessation of cortical bone growth, and diminished whole bone strength and fatigue life. J Bone Miner Res 24:1618-1627
28. Yamaguchi T, Sugimoto T (2008) Calcium homeostasis and osteoporosis in diabetes mellitus and the metabolic syndrome. Clin Calcium 18:904-911
29. Lee CT, Lien YH, Lai LW, Chen JB, Lin CR, Chen HC (2006) Increased renal calcium and magnesium transporter abundance in streptozotocin-induced diabetes mellitus. Kidney Int 69:1786-1791
30. de Luis Román DA, Aller R, Perez Castrillon JL, De Luis J, Gonzalez Sagrado M, Izaola O, Romero E, Martín Escudero JC, Herreros V (2004) Effects of dietary intake and life style on bone density in patients with diabetes mellitus type 2. Ann Nutr Metab 48:141-145 (Pubitemid 39177718)
31. Diaz VA, Mainous AG 3rd, Carek PJ, Wessell AM, Everett CJ (2009) The association of vitamin D deficiency and insufficiency with diabetic nephropathy: implications for health disparities. J Am Board Fam Med 22:521-527
32. Heaney RP (2008) Vitamin D in health and disease. Clin J Am Soc Nephrol 3:1535-1541
33. Danescu LG, Levy S, Levy J (2009) Vitamin D and diabetes mellitus. Endocr 35:11-17
34. Mathieu C, Gysemans C, Giulietti A, Bouillon R (2005) Vitamin D and diabetes. Diabetologia 48:1247-1257 (Pubitemid 41186086)
35. Zhang Y, Deb DK, Kong J, Ning G, Wang Y, Li G, Chen Y, Zhang Z, Strugnell S, Sabbagh Y, Arbeeny CM, Li YC (2009) Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Am J Physiol Ren Physiol 297:F791-F801
36. Zhang Z, Zhang Y, Ning G, Kong J, Deb DK, Li YC (2008) Combination therapy with AT1 receptor blocker and vitamin D analog markedly ameliorates diabetic nephropathy. Proc Natl Acad Sci USA 105:15896-15901
37. Holick MF (2008) Diabetes and the vitamin D connection. Curr Diab Rep 8:393-398
38. Baeke F, van Etten E, Gysemans C, Overbergh L, Mathieu C (2008) Vitamin D signaling in immune-mediated disorders: evolving insights and therapeutic opportunities. Mol Aspects Med 29:376-387
39. Panierakis C, Goulielmos G, Mamoulakis D, Petraki E, Papavasiliou E, Galanakis E (2009) Vitamin D receptor gene polymorphisms and susceptibility to type 1 diabetes in Crete, Greece. Clin Immunol 133:276-281
40. den Dekker E, Hoenderop JG, Nilius B, Bindels RJ (2003) The epithelial calcium channels, TRPV5 & TRPV6: from identification towards regulation. Cell Calcium 33:497-507 (Pubitemid 36748672)
41. Boros S, Bindels RJ, Hoenderop JG (2009) Active Ca (2+) reabsorption in the connecting tubule. Pflugers Arch 458:99-109
42. Ward DT, Yau SK, Mee AP, Mawer EB, Miller CA, Garland HO, Riccardi D (2001) Functional, molecular, and biochemical characterization of streptozotocin-induced diabetes. J Am Soc Nephrol 12:779-790 (Pubitemid 32246706)
43. Kip SN, Strehler EE (2004) Vitamin D3 upregulates plasma membrane Ca2+-ATPase expression and potentiates apico-basal Ca2 + flux in MDCK cells. Am J Physiol Ren Physiol 286:F363-F369 (Pubitemid 38141681)
44. Reidy K, Susztak K (2009) Epithelial-mesenchymal transition and podocyte loss in diabetic kidney disease. Am J Kidney Dis 54:590-593